Observational Study of HyQvia Use in Adults with Multiple Myeloma and Secondary Immunodeficiency

What this Trial Is About

Researchers are studying adults with multiple myeloma MM who have secondary immunodeficiency SID and are receiving treatment with HyQvia. This observational study aims to understand how HyQvia is used in real-world clinical settings, focusing on the details of the infusion process. The study plans to enroll about 100 participants across multiple centers in Europe and South America. Participants with MM and SID will be treated with HyQvia as part of their regular medical care. The study will track their treatment from the start of HyQvia through 12 months of follow-up. During this time, researchers will observe infusion parameters such as dose, infusion volume, rate, duration, and infusion site details. There will be no additional intervention, as the study is observational. Participants will attend multiple clinic visits over the 12 months following enrollment for follow-up assessments. Data will be collected from routine clinic visits and voluntary patient-reported outcomes. Researchers will measure various infusion characteristics and treatment outcomes, including treatment intervals, needle specifications, use of infusion pumps, caregiver support, reasons for any changes in infusion, and overall participant health status. Safety events and hospitalizations will also be monitored throughout the study period.

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency